Science Explorer Back to mapMap
Discussion
Company · Vallejo · United States

MyeloRx (United States)

myelorx.comROR OpenAlex
Research works
4
fractional, all time
Citations
43
10.1 per fractional work
Top-10% rate
9.0%
all institutions 10.0%
Open access
29%
world 40%
MyeloRx (United States)

Not ranked overall: MyeloRx (United States) is under the volume floor below which a citation excellence rate is noise. Not ranked is not the same as ranked last.

Which fields of science does MyeloRx (United States) work in?

In all years, 53% of research at MyeloRx (United States) is in Life Sciences, 47% in Health Sciences. Its largest fields are Biochemistry, Genetics and Molecular Biology (53%), Medicine (47%). It does 1.5× the world's share of Life Sciences.

Life Sciences: 2 fractional works · 53.5% of its workBiochemistry, Genetics and Molecular Biology: 2 fractional works · 53.5% of its workHealth Sciences: 2 fractional works · 46.5% of its workMedicine: 2 fractional works · 46.5% of its workALL ITS WORKMyeloRx (UnitedStates)4fractional works, all years
Life Sciences53%Health Sciences47%

Each ring splits the one inside it: the four domains of science, their fields. Size is fractional works in all years. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.

Its 2 domains and 2 fields, with their numbers
    1. Biochemistry, Genetics and Molecular Biology253.5%
    1. Medicine246.5%
All of science, and how each field's share has moved since 1950: the Science domain explorer

What are the most cited papers from MyeloRx (United States)?

The most cited paper from MyeloRx (United States) is "MRx102, a triptolide derivative, has potent antileukemic activity in vitro and in a murine model of AML" (B Z Carter, Duncan H. F. Mak, Yue Xi Shi et al., 2011), with 43 citations. Next come "The triptolide derivative MRx102 inhibits Wnt pathway activation and has potent anti-tumor effects in lung cancer" (37) and "Preclinical antileukemic activity, toxicology, toxicokinetics and formulation development of triptolide derivative MRx102" (20).

Most cited papers
#PaperReleasedCitations
1 MRx102, a triptolide derivative, has potent antileukemic activity in vitro and in a murine model of AML B Z Carter, Duncan H. F. Mak, Yue Xi Shi et al. · Leukemia Open access 9 Sep 2011 43
2 The triptolide derivative MRx102 inhibits Wnt pathway activation and has potent anti-tumor effects in lung cancer Theresa A. Reno, Sun-Wing Tong, Jun Wu et al. · BMC Cancer Open access 11 Jul 2016 37
3 Preclinical antileukemic activity, toxicology, toxicokinetics and formulation development of triptolide derivative MRx102 John M. Fidler, Jinhua An, Bing Z. Carter et al. · Cancer Chemotherapy and Pharmacology Open access 11 Mar 2014 20
4 Preclinical Development of Triptolide Derivative MRx102 as a Therapeutic Agent for Acute Myeloid Leukemia John M. Fidler, Jinhua An, JOHN H. MUSSER et al. · Blood 19 Nov 2010 1
5 MRx102, a Novel Triptolide Analogue, Has Low Nanomolar Activity Against AML Stem/Progenitor Cells in Vitro and in a Murine Model of AML Bing Z. Carter, Duncan H. F. Mak, Yuxie Shi et al. · Blood 18 Nov 2011 0
All 6 most cited papers, with filters and sorting

Which research topics does MyeloRx (United States) publish most on?

By volume in 2022-now: Diabetes Management and Research, Diabetes and associated disorders and Cardiovascular Health and Risk Factors.

Diabetes Management and …0Diabetes Management and Research: 0 fractional worksDiabetes and associated …0Diabetes and associated disorders: 0 fractional worksCardiovascular Health an…0Cardiovascular Health and Risk Factors: 0 fractional works
Endocrinology, Diabetes and MetabolismGeneticsCardiology and Cardiovascular Medicine

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 Diabetes Management and Research Endocrinology, Diabetes and Metabolism 0 works
  2. 2 Diabetes and associated disorders Genetics 0 works
  3. 3 Cardiovascular Health and Risk Factors Cardiology and Cardiovascular Medicine 0 works

How open and international is its research?

Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available29.4%not open70.6%

World: 40% of research is openly available.

How has MyeloRx (United States)'s research output changed?

still counting201520202025
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Other research institutions in Vallejo

All research institutions in Vallejo

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.

Discussion

Ask a question or share a note about MyeloRx (United States). Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.